Please try another search
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company’s preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Eric Floyd | 61 | 2017 | Independent Chairman |
Michael F. Dubin | 68 | 2021 | Independent Director |
Barbara A. Ruskin | 63 | 2023 | Independent Director |
Gerald W. Bruce | 67 | 2017 | CEO & Director |
Vanila M. Singh | 53 | 2020 | Independent Director |
Jerrold B. Sendrow | 79 | 2017 | Independent Director |
Thani Jambulingam | 60 | 2017 | Independent Director |
Jeffrey A. Gudin | 58 | 2017 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review